Asset Details
MbrlCatalogueTitleDetail
Do you wish to reserve the book?
Introducing 'Health Vulnerability'. Towards a Human Right Claim for Innovative Orphan Drugs?
by
Gennet, Éloïse
in
Humanities and Social Sciences
/ Law
2020
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
Introducing 'Health Vulnerability'. Towards a Human Right Claim for Innovative Orphan Drugs?
by
Gennet, Éloïse
in
Humanities and Social Sciences
/ Law
2020
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Introducing 'Health Vulnerability'. Towards a Human Right Claim for Innovative Orphan Drugs?
Journal Article
Introducing 'Health Vulnerability'. Towards a Human Right Claim for Innovative Orphan Drugs?
2020
Request Book From Autostore
and Choose the Collection Method
Overview
Abstract
Although several European law instruments specifically promote the development of orphan medicines, rare disease patients still suffer from an excessive lack of access to orphan drugs. In order to base a claim for equity of access to research benefits, health vulnerability is introduced as a human rights-based public health concept. It represents a potentially valuable and powerful means in European law for rare disease patients to claim for an improved public action to develop innovative orphan drugs, including through the use of novel data-driven technologies such as computer modelling and simulation, as they have the potential to palliate some of the obstacles in the current development process of orphan medicines. The human rights-based approach would be all the more valuable, as it would simultaneously draw attention on privacy aspects of vulnerability for orphan disease patients, especially regarding increased risks stemming from the processing of highly sensitive health data.
Publisher
Brill | Nijhoff,Brill Academic Publishers
Subject
This website uses cookies to ensure you get the best experience on our website.